©2026 Bryn Mawr Communications, LLC.
All Rights Reserved

Terms and Conditions • Privacy Policy

Contributor:

Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab
Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab

Ben Young, MD; Pheobe Mellen, MD; and Jordan Deaner, MD

Diabetic Retinopathy Severity and Income Status
Diabetic Retinopathy Severity and Income Status

Ben Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD

New Retina Radio Journal Club w/ VBS: RVOs During the COVID Pandemic
New Retina Radio Journal Club w/ VBS: RVOs During the COVID Pandemic

Katherine Talcott, MD; Phoebe Mellen, MD and Kyle Kovacs, MD

New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO
New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO

Katherine Talcott, MD; Kyle Kovacs, MD; and Phoebe Mellen, MD

New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab

Ben Young, MD; Pheobe Mellen, MD; and Jordan Deaner, MD

Diabetic Retinopathy Severity and Income Status

Ben Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD

New Retina Radio Journal Club w/ VBS: RVOs During the COVID Pandemic

Katherine Talcott, MD; Phoebe Mellen, MD and Kyle Kovacs, MD

New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO

Katherine Talcott, MD; Kyle Kovacs, MD; and Phoebe Mellen, MD